AR124419A1 - Células seguras invisibles para el sistema inmunitario - Google Patents

Células seguras invisibles para el sistema inmunitario

Info

Publication number
AR124419A1
AR124419A1 ARP210103566A ARP210103566A AR124419A1 AR 124419 A1 AR124419 A1 AR 124419A1 AR P210103566 A ARP210103566 A AR P210103566A AR P210103566 A ARP210103566 A AR P210103566A AR 124419 A1 AR124419 A1 AR 124419A1
Authority
AR
Argentina
Prior art keywords
mammalian cell
genes
hsv
immune system
gene
Prior art date
Application number
ARP210103566A
Other languages
English (en)
Inventor
Jay Chaplin
Ulrik Dhn
Thomas Frogne
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR124419A1 publication Critical patent/AR124419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: La célula de mamífero que comprende un gen de fusión B2M / HLA-E, que no comprende otros genes de B2M expresables y que tiene incorporaciones de al menos 4 genes de HSV-TK en ubicaciones distintas y conocidas, en donde al menos uno de dichos 4 genes de HSV-TK es un gen de TK-sr39. Reivindicación 9: Un método para producir una célula de mamífero implantable, que comprende las etapas de: proporcionar una célula de mamífero, incorporar al menos un gen de fusión B2M / HLA-E en dicha célula de mamífero, inactivar los genes de B2M nativa de dicha célula de mamífero, incorporar al menos 4 genes de HSV-TK en ubicaciones distintas y conocidas, en donde al menos uno de dichos 4 genes de HSV-TK es un gen de TK-sr39, opcionalmente diferenciar dicha célula de mamífero, de manera que se obtiene dicha célula de mamífero implantable.
ARP210103566A 2020-12-18 2021-12-17 Células seguras invisibles para el sistema inmunitario AR124419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20215272 2020-12-18

Publications (1)

Publication Number Publication Date
AR124419A1 true AR124419A1 (es) 2023-03-29

Family

ID=73855659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103566A AR124419A1 (es) 2020-12-18 2021-12-17 Células seguras invisibles para el sistema inmunitario

Country Status (3)

Country Link
AR (1) AR124419A1 (es)
TW (1) TW202242095A (es)
WO (1) WO2022129472A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008979A1 (en) 2022-09-30 2024-01-11 Novo Nordisk A/S A sirp-alpha binding chimeric protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2003055992A2 (en) 2001-12-28 2003-07-10 Cellartis Ab A method for the establishment of a pluripotent human blastocyst-derived stem cell line
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
AU2006301549B2 (en) 2005-10-07 2013-02-14 Cellartis Ab A method for obtaining a xeno-free hBS cell line
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
DK2699593T4 (da) 2011-04-20 2021-02-08 Univ Washington Through Its Center For Commercialization Beta-2 mikroglobulin-deficiente celler
EP3039122B1 (en) 2013-08-30 2019-07-17 Novo Nordisk A/S Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules
SG11201803144WA (en) * 2015-11-04 2018-05-30 Fate Therapeutics Inc Genomic engineering of pluripotent cells
CN108699515A (zh) 2016-02-24 2018-10-23 诺和诺德股份有限公司 由人多能干细胞衍生的内分泌祖细胞生成功能性β细胞
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3665271A4 (en) 2017-08-08 2021-04-28 Sangamo Therapeutics, Inc. CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
WO2019241400A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Stem cell-engineered inkt cell-based off -the-shelf cellular therapy
JP2021534813A (ja) * 2018-07-13 2021-12-16 ロタール ゲルメロート 非免疫原性の操作された組織ならびにそれを製造および使用する方法
DK3833682T3 (da) * 2018-10-01 2022-10-03 Caribou Biosciences Inc Selvmordsmolekyle sammensætninger og fremgangsmåder

Also Published As

Publication number Publication date
TW202242095A (zh) 2022-11-01
WO2022129472A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
EA201991849A1 (ru) Система и способ редактирования генома
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
Taylor et al. Heterogeneity in the differentiation and function of memory B cells
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
BR112019008560A2 (pt) célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação
Sanz et al. Biosynthesis of GDP-fucose and other sugar nucleotides in the blood stages of Plasmodium falciparum
AR124419A1 (es) Células seguras invisibles para el sistema inmunitario
AR107278A1 (es) Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
BR112015027996A2 (pt) organoides compreendendo células renais isoladas e suas utilizações
BR112016007919A2 (pt) vacinas atenuadas vivas
CY1112351T1 (el) ΛΗΨΗ ΚΥΤΤΑΡΩΝ Tr1, ΕΙΔΙΚΩΝ ΓΙΑ ΑΝΤΙΓΟΝΑ ΤΡΟΦΙΜΟΥ Ή ΓΙΑ ΑΥΤΟΑΝΤΙΓΟΝΑ ΑΠΟ ΕΝΑΝ ΠΛΗΘΥΣΜΟ ΛΕΥΚΟΚΥΤΤΑΡΩΝ PBMC
BR112021014645A2 (pt) Método de edição de genes
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
BR112016012229A2 (pt) métodos de produção de polipeptídeos
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
Braid et al. Engineered mesenchymal cells improve passive immune protection against lethal Venezuelan equine encephalitis virus exposure
ECSP22051779A (es) Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos
CN104131018A (zh) 一种细胞内蛋白自诱导表达的方法
Hjelm et al. Autotransporter-based antigen display in bacterial ghosts
CY1122993T1 (el) Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων
EA202191360A1 (ru) Усовершенствованное получение рибофлавина
CL2011003104A1 (es) Metodo para la elaboracion de acidos grasos no saturados, basado en el cultivo de una celula que expresa un polipeptido heterologo con actividad esaturasa/enoil-coa reductasa celula huesped, complejo elongasa que comprende dicho polipeptido y uso de la misma.
AR069885A1 (es) Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional

Legal Events

Date Code Title Description
FB Suspension of granting procedure